Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21516067 | 0.81 | RXRA (0.31) | RXRAGRIN1GRIN2B | |
| SCHEMBL12120619 | 0.76 | RXRA (0.33) | RXRAGRIN1GRIN2B | |
| SCHEMBL18494814 | 0.75 | RXRA (0.32) | RXRAGRIN1GRIN2B | |
| SCHEMBL18950388 | 0.75 | APLNR (0.35) | RXRAGRIN1GRIN2B | |
| SCHEMBL22725522 | 0.74 | — | — | |
| SCHEMBL21186473 | 0.73 | ESR1 (0.35) | — | |
| SCHEMBL20341255 | 0.71 | RXRA (0.30) | RXRAGRIN1GRIN2B | |
| SCHEMBL10267302 | 0.70 | RXRA (0.33) | RXRAGRIN1GRIN2B | |
| SCHEMBL26532695 | 0.70 | CYP3A4 (0.33) | RXRAGRIN1GRIN2B | |
| SCHEMBL23194584 | 0.69 | RXRA (0.35) | RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-08-17 | — | — | US | disclosed |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | MAP2K2, MAP2K5, MAP2K4 | RXRA 3159/4885GRIN1 1480/4885GRIN2B 2055/4885 |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | MAP2K2, MAP2K4, MAP2K5 | RXRA 3219/4885GRIN1 1612/4885GRIN2B 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.